The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease

Netherlands Heart Journal

Volumn 19, Issue 2, 2011, Pages 85-88

  Janssens, A C J W ^a   Wilde, A A M ^b   van Langen, I M ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Direct to consumer; Genetic testing; Predictive ability; Risk assessment

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMERCIAL PHENOMENA; DIRECT TO CONSUMER; GENE FREQUENCY; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HUMAN; LIFESTYLE MODIFICATION; PHYSICAL ACTIVITY; PREDICTION; PREDICTIVE VALUE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 79955438704     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-010-0069-x     Document Type: Article

References (26)

1. Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA. 2005;294:1399-402.
2. Brand A, Brand H, Schulte In den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet. 2008;16:5-13.
3. Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol. 2010;55:2570-6.
4. Alders M, Koopmann TT, Christiaans I, et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. Am J Hum Genet. 2009;84:468-76.
5. Christiaans I, Birnie E, van Langen IM, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomy- opathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J. 2010;31:842-8.
6. Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010;31:926-35.
7. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165-8.
8. van Langen IM, Hofman N, Tan HL, et al. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med. 2004;36 Suppl 1:116-24.
9. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
10. Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-7.
11. Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2007;166:28-35.
12. Anderson JL, Horne BD, Camp NJ, et al. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J. 2010;160:250-6.
13. Bare LA, Morrison AC, Rowland CM, et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med. 2007;9:682-9.
14. Janssens ACJW, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008;82:593-9.
15. Manolio TA. Genome-wide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.
16. van der Net JB, Janssens ACJW, Defesche JC, et al. Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterol- emia. Am J Cardiol. 2009;103:375-80.
17. Swan M. Multigenic condition risk assessment in direct-to- consumer genomic services. Genet Med. 2010;12:279-88.
18. Mihaescu R, van Hoek M, Sijbrands EJ, et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med. 2009;11:588-94.
19. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240-9.
20. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-3.
21. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65-72.
22. Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008;54:467-74.
23. Howard HC, Borry P. Personal genome testing: do you know what you are buying? Am J Bioeth. 2009;9:11-3.
24. McGuire AL, Diaz CM, Wang T, et al. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009;9:3-10.
25. Johansen CT, Lanktree MB, Hegele RA. Translating genomic analyses into improved management of coronary artery disease. Future Cardiol. 2010;6:507-21.
26. Janssens ACJW, Van Duijn CM. An epidemiological perspective on the future of direct-to-consumer personal genome testing. Investigative Genetics. 2010;1:10.